Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass

Saved in:
Bibliographic Details
Published inAnesthesiology (Philadelphia) Vol. 92; no. 1; pp. 263 - 266
Main Authors LATHAM, P, REVELIS, A. F, JOSHI, G. P, DIMAIO, J. M, JESSEN, M. E
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott 2000
Subjects
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Cardiopulmonary Bypass
Fatal Outcome
Heart Valve Prosthesis Implantation
Heparin - adverse effects
Hirudin Therapy
Hirudins - analogs & derivatives
Humans
Intraoperative Period
Male
Medical sciences
Middle Aged
Mitral Valve
Multiple Organ Failure
Partial Thromboplastin Time
Pharmacology. Drug treatments
Postoperative Complications
Recombinant Proteins - therapeutic use
Thrombocytopenia - chemically induced
Thrombocytopenia - complications
Thrombosis - chemically induced
Thrombosis - complications
Heart
Human
Thrombocytopenia
Blood coagulation
Toxicity
Cardiovascular disease
Hemopathy
Anticoagulant
Thrombosis
Hirudin
Vascular disease
Cardiopulmonary bypass
Case study
Platelet
Heart disease
Surgery
Partial thromboplastin time
Glycosaminoglycan
Heparin
Recombinant protein
Monitoring
Online AccessGet full text

Cover

More Information
ISSN:0003-3022
1528-1175
DOI:10.1097/00000542-200001000-00040